Notification
No new Notification messages
Khyati Global Ventures IPO is Open!
Apply for the Khyati Global Ventures IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
Trade Now, Pay Later with up to 4x Leverage
Never miss a good trading opportunity due to low funds with our MTF feature.

Mankind Pharma Secures All Approvals For BSV Acquisition

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Mankind Pharma obtained all regulatory approvals, including from CCI, for its ₹13,630 crore acquisition of Bharat Serums and Vaccines. The transaction involves acquiring a 100% stake in BSV.

Mankind Pharma news today

Mankind Pharma Ltd. has successfully received all the necessary regulatory approvals, including the green light from the Competition Commission of India (CCI), to complete its 100% acquisition of Bharat Serums and Vaccines Ltd. (BSV). The acquisition, valued at ₹13,630 crore, marks a significant milestone in Mankind Pharma's expansion strategy in the biopharmaceutical and vaccine sector.

MANKIND PHARMA LIMITED

Trade

2611.6573.84 (2.90 %)

Updated - 04 October 2024
2620.00day high
DAY HIGH
2514.70day low
DAY LOW
364821
VOLUME (BSE)

Acquisition details and approvals

The company announced the execution of a Share Purchase Agreement on 25 July 2024. The agreement involves the acquisition of Bharat Serums and Vaccines Ltd. from Ansamira Ltd. and Miransa Ltd., affiliates of funds managed by Advent International, along with minority shareholders Bhaskar Iyer and Abhijit Mukherjee. The deal includes acquiring 100% of BSV's shares, making Mankind Pharma a key player in the biopharmaceutical market.

Mankind Pharma disclosed that the transaction is now subject to the completion of customary conditions precedent, as detailed in the Share Purchase Agreements. However, with regulatory hurdles cleared, the acquisition is expected to proceed smoothly.

The strategic significance of the acquisition

Bharat Serums and Vaccines Ltd. specialises in the development and manufacturing of biopharmaceuticals, vaccines, and critical-care products, with a portfolio that includes treatments for immunology, oncology, and gynaecology. The acquisition aligns with Mankind Pharma's strategy of expanding its product offerings and tapping into high-growth therapeutic areas. This acquisition is expected to strengthen Mankind Pharma's position in the Indian and global pharmaceutical markets.

Financial implications

The acquisition deal is valued at ₹13,630 crore, positioning it as one of the largest in the Indian pharmaceutical industry this year. The acquisition is anticipated to drive growth for Mankind Pharma by enhancing its presence in key markets and diversifying its product portfolio. Investors will closely watch Mankind Pharma's share price as the company integrates BSV into its operations and explores potential synergies.

Mankind Pharma’s acquisition of Bharat Serums and Vaccines Ltd. is a strategic move that solidifies its position in the biopharmaceutical sector. With regulatory approvals secured, the completion of the transaction is on the horizon, promising growth and market expansion.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text